Prothena Corporation Liabilities 2024

Prothena Corporation Aktienanalyse

What does Prothena Corporation do?

Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Prothena Corporation's Liabilities

Prothena Corporation's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Prothena Corporation's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Prothena Corporation's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Prothena Corporation's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Prothena Corporation’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Prothena Corporation stock

What is the level of liabilities of Prothena Corporation this year?

Prothena Corporation has a debt balance of 135.02 M USD this year.

What were the liabilities of Prothena Corporation compared to the previous year?

The liabilities of Prothena Corporation have increased by -0.72% dropped compared to the previous year.

What are the consequences of high debt for investors of Prothena Corporation?

High liabilities can pose a risk for investors of Prothena Corporation, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Prothena Corporation?

Low liabilities mean that Prothena Corporation has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Prothena Corporation affect the company?

An increase in liabilities of Prothena Corporation can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Prothena Corporation affect the company?

A decrease in the liabilities of Prothena Corporation can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Prothena Corporation?

Some factors that can influence the liabilities of Prothena Corporation include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Prothena Corporation so important for investors?

The liabilities of Prothena Corporation are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Prothena Corporation take to modify the liabilities?

To change its liabilities, Prothena Corporation can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Prothena Corporation pay?

Over the past 12 months, Prothena Corporation paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Prothena Corporation is expected to pay a dividend of 0 USD.

What is the dividend yield of Prothena Corporation?

The current dividend yield of Prothena Corporation is .

When does Prothena Corporation pay dividends?

Prothena Corporation pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Prothena Corporation?

Prothena Corporation paid dividends every year for the past 0 years.

What is the dividend of Prothena Corporation?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Prothena Corporation located?

Prothena Corporation is assigned to the 'Health' sector.

Wann musste ich die Aktien von Prothena Corporation kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Prothena Corporation from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Prothena Corporation pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Prothena Corporation in the year 2023?

In the year 2023, Prothena Corporation distributed 0 USD as dividends.

In which currency does Prothena Corporation pay out the dividend?

The dividends of Prothena Corporation are distributed in USD.